Our Biomarkers team, in collaboration with Dr. Thomas Luft group at the Heidelberg University Hospital (Germany), explored the role of tryptophan metabolites in the acute and chronic graft versus host disease (GVHD) following allogenic bone marrow transplantation. GVHD is an…
Following the first report in the Journal of Medicinal Chemistry in 2020, the IRBM peptide chemistry group is proud to announce a new publication on second generation, potent bi- and tricyclic PCSK9 inhibitor peptides in collaboration with the extraordinary drug discovery team at Merck & co.
Our Peptide Chemistry team, in collaboration with scientists at Merck and Co., reported on the design, synthesis and characterization of potent and stable peptides able to inhibit the binding of NRF2-MAFG heterodimeric transcription factor to Antioxidant Response Element (ARE) DNA sequence.
At IRBM we are passionate about helping companies develop medicines in a wide range of diseases and our scientists support the fundamental understanding of disease mechanisms. Science is about collaboration, and publication is an integral part of the scientific process.
UniQure has just published a study in Science Translational Medicine using a Huntingtin (HTT)-lowering therapy. IRBM is delighted to have been able to contribute to this pivotal work and to be cited on the publication. Huntingtin is the gene that…
Our integrated drug discovery efforts on the Relaxin-2 peptide hormone, in collaboration with our collaborators at global life sciences company Sanofi, has produced a paper just published in the Journal of Medicinal Chemistry. The natural peptide hormone human relaxin-2 has…
